Drug
Defactinib clinical trials
Also written VS-6063 and PF-04554878.
Includes 3 studies of Defactinib hydrochloride.
- studies test it
- 31
- open now
- 10
- in phase 3
- 1
- first study started
- 2008
Keep track of what changes. Save the defactinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- VS-6063
- 13
Combined with it in one product
Studies by the year they started
30 studies that test it; most in 2013 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2013 | 5 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 13
- Phase 2
- 18
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 20
Verastem, Inc. (11) · Memorial Sloan Kettering Cancer Center (3) · Washington University School of Medicine (3) · National Cancer Institute (NCI) (2) · Emory University (2) · M.D. Anderson Cancer Center (2) · Institute of Cancer Research, United Kingdom (1) · Lei Zheng (1)
Often tested with
Tested in the same studies.
RO5126766 (14) · Nivolumab (2) · Pembrolizumab (2) · Adavosertib (1) · Afatinib (1) · Binimetinib (1) · Capivasertib (1) · Copanlisib (1)
Studies
Open first, then newest update. How each study uses defactinib is read from its arms, and is right about nine times in ten.
Testing it · 31
- A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06394804Written as Defactinib
- A Study of Avutometinib and Defactinib in People With Thyroid CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06007924Written as Defactinib
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 3Verastem, Inc.NCT06072781Written as Defactinib
- Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT06369259Written as Defactinib
- Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath TumorNot yet recruitingPhase 2Girish Dhall, MDNCT07743554Written as avutometinib capsule + defactinib tablet
- Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT07318324Written as defactinib
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaRecruitingPhase 2Washington University School of MedicineNCT07126158Written as Defactinib
- Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerRecruitingPhase 2Emory UniversityNCT06495125Written as Defactinib
- Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSRecruitingPhase 1Clinical Hub for Interventional Research (CHOIR)NCT05636514Written as Defactinib
- Avutometinib and Defactinib in Diffuse Gastric CancerRecruitingPhase 2Ryan H. Moy, MD, PhDNCT06487221Written as Defactinib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Defactinib
- A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05787561Written as Defactinib
- Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas AdenocarcinomaActive, not recruitingPhase 2Washington University School of MedicineNCT04331041Written as Defactinib
- Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439331Written as Defactinib Hydrochloride
- Phase I Trial of Defactinib and VS-6766.Active, not recruitingPhase 1Institute of Cancer Research, United KingdomNCT03875820Written as Defactinib
- Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal AdenocarcinomaCompletedPhase 2Lei ZhengNCT03727880Written as Defactinib
- Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive, not recruitingPhase 1/2Verastem, Inc.NCT05074810Written as avutometinib and sotorasib and defactinib
- Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With GlioblastomaActive, not recruitingEarly Phase 1Emory UniversityNCT05798507Written as Defactinib
- Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal MelanomaTerminatedPhase 2Thomas Jefferson UniversityNCT04720417Written as Defactinib Hydrochloride
- Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma ParticipantsTerminatedPhase 2Verastem, Inc.NCT02004028Written as VS-6063
See all 31 studies that test defactinib →
Given in every arm · 4 — defactinib is usual care beside what is tested
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Defactinib
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain TumoursRecruitingPhase 1/2Institute of Cancer Research, United KingdomNCT06630260Written as Defactinib
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaRecruitingPhase 1/2University of UtahNCT06194929Written as Defactinib
- ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAKTerminatedPhase 1/2Michael McHaleNCT03287271Written as VS-6063
Codes
What other systems call defactinib · ClinicalTrials.gg INT006376
- MeSH (NLM) C584510defactinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 53O87HA2QUDEFACTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27077009defactinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C79809DefactinibOne source FDA
- DrugBank DB12282One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584510 | defactinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 53O87HA2QU | DEFACTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27077009 | defactinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C79809 | Defactinib | One source FDA |
| DrugBank | DB12282 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.